Evidence map›Paper›PMID 42903845›Full record

ArticleiScience2026

Quantitative systems pharmacology modeling of class I-III BRAF-mutant NSCLC enables subgroup treatment analysis and combination therapy design.

Jingjing Hu, Qi Rao, Zichun Li, Geli Li, Zhenle Bi, Danyi Wen, Chen Zhao, Guohua Zhou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jingjing HuDepartment of Clinical Pharmacy, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Qi RaoSchool of Pharmacy, Nanjing Medical University, Nanjing, China.
Zichun LiSchool of Pharmacy, Nanjing Medical University, Nanjing, China.
Geli LiSchool of Pharmacy, Nanjing Medical University, Nanjing, China.
Zhenle BiShanghai LIDE Biotech Co., Ltd., Shanghai, China.
Danyi WenShanghai LIDE Biotech Co., Ltd., Shanghai, China.
Chen ZhaoSchool of Pharmacy, Nanjing Medical University, Nanjing, China.
Guohua ZhouDepartment of Clinical Pharmacy, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BRAF-mutant non-small cell lung cancer (NSCLC) comprises three functional classes (I-III) with distinct driving mechanisms, yet effective therapies for classes II and III remain limited. To address this, we developed a quantitative systems pharmacology (QSP) model that mechanistically recapitulates signaling networks and drug responses across all three classes, integrating multiscale preclinical-to-clinical datasets. The model enabled high-throughput prediction of clinical efficacy for monotherapies and combination therapies across diverse dosing regimens, and we identified that combining MEK and ERK inhibition represents a novel strategy for class II/III mutants, validated by original

Indexed as

BRAFcombination therapydrug resistancequantitative systems pharmacologyrare mutationsvirtual clinical trials

Identifiers

PMID42903845
PMCPMC13682387

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.